Dose-Dense AC Followed by Taxol With Herceptin Is Feasible
A mature 70-patient report by Chau T. Dang, MD, et al, on cardiac safetyof dose-dense AC (doxorubicin and cyclophosphamide, 60/600 mg/m2 X4) followed by Taxol with Herceptinfor 52 weeks in HER2-positivepatients, has concluded that theregimen is feasible; 3 of 70 patients (4%) had cessation oftrastuzumab because of asymptomaticLVEF decline, about 6 monthsinto the treatment period.
A mature 70-patient report by ChauT. Dang, MD, et al, on cardiac safetyof dose-dense AC (doxorubicin andcyclophosphamide, 60/600 mg/m2 ×4) followed by Taxol with Herceptinfor 52 weeks in HER2-positivepatients, has concluded that theregimen is feasible (abstract 2101); 3of 70 patients (4%) had cessation oftrastuzumab because of asymptomaticLVEF decline, about 6 monthsinto the treatment period. No significantLVEF declines were observedafter dose-dense AC, as assessed bymonth 2 MUGA. One patient hadCHF at month 4 of treatment (baselineEF > 75% dropped to 45%). Investigatorsreported she is clinically wellon diuretic, ACE-inhibitor, and beta-blocker.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
